Correlation Between Puma Biotechnology and Zentalis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Zentalis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Zentalis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Puma Biotechnology and Zentalis Pharmaceuticals Llc, you can compare the effects of market volatilities on Puma Biotechnology and Zentalis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Zentalis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Zentalis Pharmaceuticals.

Diversification Opportunities for Puma Biotechnology and Zentalis Pharmaceuticals

-0.01

Correlation Coefficient

Puma Biotechnology  Zentalis Pharmaceuticals

Good diversification

The 3 months correlation between Puma and Zentalis is -0.01. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Zentalis Pharmaceuticals Llc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zentalis Pharmaceuticals and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Zentalis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zentalis Pharmaceuticals has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Zentalis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Puma Biotechnology and Zentalis Pharmaceuticals

Given the investment horizon of 90 days Puma Biotechnology is expected to generate 0.77 times more return on investment than Zentalis Pharmaceuticals. However, Puma Biotechnology is 1.29 times less risky than Zentalis Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Zentalis Pharmaceuticals Llc is currently generating about -0.01 per unit of risk. If you would invest  309.00  in Puma Biotechnology on September 16, 2024 and sell it today you would lose (21.00) from holding Puma Biotechnology or give up 6.8% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Puma Biotechnology  vs.  Zentalis Pharmaceuticals Llc

Puma Biotechnology

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Zentalis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Pair Trading with Puma Biotechnology and Zentalis Pharmaceuticals

The main advantage of trading using opposite Puma Biotechnology and Zentalis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Zentalis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zentalis Pharmaceuticals will offset losses from the drop in Zentalis Pharmaceuticals' long position.

The idea behind Puma Biotechnology and Zentalis Pharmaceuticals Llc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.